Tobira Therapeutics Inc (RGDO)
Tobira Therapeutics is a development stage biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Co. is engaged in the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. Co.'s primary product candidate, REG1, consists of pegnivacogin, a highly potent and selective anticoagulant, and anivamersen, its specific active control agent. Co. is developing REG1 as an anticoagulant for use in patients with a variety of cardiovascular conditions undergoing percutaneous coronary intervention.
|
March 29, 2024 9:37 AM Eastern
Hold (2.00 out of 4)
100th percentile
|
|